Atopic dermatitis and skin diseaseRNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications
Section snippets
Patients and samples
Biopsy specimens of lesional and nonlesional skin were collected from 20 consented patients with moderate-to-severe AD included in our cyclosporin A (CsA) study (see Table E1 in this article's Online Repository at www.jacionline.org).13 Sera from 8 healthy subjects (4 male and 4 female subjects; age, 26-57 years [median, 32 years]) were collected for comparison of soluble triggering receptor expressed on myeloid cells 1 (TREM-1) levels (see Table E1).
RT-PCR and microarrays
RT-PCR was performed on 34 preselected
Results
In this study we used the same cohort of patients with moderate-to-severe AD treated with CsA13, 19 for whom genomic profiles were simultaneously obtained with Affymetrix Human Genome U133APlus 2.0 (GSE#58558) and RNA-seq by using Illumina HiSeq2500 (100 cycles, single-read sequencing, 4 samples per lane). RT-PCR on 34 preselected AD genes served for comparison (Fig 1). Two patients were excluded after quality control. Thus the analysis cohort for microarray and RNA-seq analyses included 18
Discussion
Genomic skin profiling has gained acceptance as a sensitive tool to measure early disease improvement in patients with psoriasis36, 37, 38 and, lately, also in AD clinical trials of emerging therapeutics.3, 13, 16 These studies primarily use microarrays to define relevant disease transcriptomes, with good correlations between the clinical disease improvements (by Psoriasis Area and Severity Index36, 38 and SCORAD or Eczema Area and Severity Index scores)13, 14, 16 and the molecular changes in
References (51)
- et al.
Quality-of-life outcomes and measurement in childhood atopic dermatitis
Immunol Allergy Clin North Am
(2010) - et al.
Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis
J Allergy Clin Immunol
(2012) - et al.
Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB
J Allergy Clin Immunol
(2013) - et al.
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology
J Allergy Clin Immunol
(2014) - et al.
Dupilumab improves the molecular signature in the skin of patients with severe atopic dermatitis
J Allergy Clin Immunol
(2014) - et al.
Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis
J Allergy Clin Immunol
(2014) - et al.
Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence
J Allergy Clin Immunol
(2014) - et al.
Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS
Cytokine
(2013) - et al.
TREM-1 as a potential therapeutic target in psoriasis
J Invest Dermatol
(2013) - et al.
IL-36R ligands are potent regulators of dendritic and T cells
Blood
(2011)
Biology of IL-36 cytokines and their role in disease
Semin Immunol
Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis
J Invest Dermatol
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
J Allergy Clin Immunol
Transcriptional profiling of psoriasis using RNA-seq reveals previously unidentified differentially expressed genes
J Invest Dermatol
Transcriptome Analysis of psoriasis in a large case-control sample: RNA-Seq provides insights into disease mechanisms
J Invest Dermatol
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis
J Allergy Clin Immunol
Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches
J Allergy Clin Immunol
The translational revolution and the use of biologics in inflammatory skin diseases
J Allergy Clin Immunol
Regulation of T lymphocyte activation by microRNA-21
Mol Immunol
MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sezary syndrome
J Invest Dermatol
miR-142-3p enhances FcepsilonRI-mediated degranulation in mast cells
Biochem Biophys Res Commun
Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection
J Allergy Clin Immunol
A population-based survey of eczema prevalence in the United States
Dermatitis
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis
N Engl J Med
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities
J Allergy Clin Immunol
Cited by (214)
Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativa
2024, Journal of the American Academy of DermatologyEmerging Role of the IL-36/IL-36R Axis in Multiple Inflammatory Skin Diseases
2024, Journal of Investigative DermatologySingle-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis
2023, Journal of Allergy and Clinical ImmunologyAssessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology
2023, Journal of Investigative DermatologyCrisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin
2023, Journal of the American Academy of DermatologyAltered RNA Editing in Atopic Dermatitis Highlights the Role of Double-Stranded RNA for Immune Surveillance
2023, Journal of Investigative Dermatology
Supported in part by grant no. UL1 TR000043 from the National Center for Advancing Translational Sciences (NCATS), a National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program. Also supported by a research grant to E.G.-Y. from Bristol-Myers Squibb. D.A.E is a joint PhD student of Leo Pharma and DTU and partly funded by the Danish Ministry of Higher Education and Science.
Disclosure of potential conflict of interest: This study was funded by Bristol-Myers Squibb and the National Institutes of Health. D. A. Ewald is employed by LEO Pharma AS and has received or has grants pending from the Danish Ministry of Higher Education and Science. S. R. Dillon is employed by ZymoGenetics and holds stock options in this Bristol-Myers Squibb. J. G. Krueger's institution has received funding from Novartis, Pfizer, Amgen, Lilly, Merck, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, Bristol-Myers Squibb, Serono, Jamssen, Paraxel, and he has received personal fees from Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Xenoport, and Kineta. E. Guttman-Yassky has received compensation for board membership from Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, Medimmune, Celgene, Anacor, and Leo Pharma, as well as consultancy fees from Regeneron, Sanofi Aventis, Medimmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, and Drais; and her institution has received or has grants pending from Regeneron, Celgene, BMS, and Janssen. The rest of the authors declare that they have no relevant conflicts of interest.